Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

S9626: Megestrol in Treating Hot Flashes Following Treatment for Breast Cancer

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Southwest Oncology Group
ClinicalTrials.gov Identifier:
NCT00005975
First received: July 5, 2000
Last updated: November 17, 2015
Last verified: November 2015

July 5, 2000
November 17, 2015
April 1998
September 2001   (final data collection date for primary outcome measure)
Effectiveness and duration of the benefit of placebo and 2 dose levels of megestrol acetate in reduction of severe and/or frequent hot flashes in patients with history of adequate local and regional treatment of invasive breast cancer [ Time Frame: 3, 6, and 9 months ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00005975 on ClinicalTrials.gov Archive Site
  • Document any effects of various dose levels of megestrol acetate on atrophic vaginitis and dyspareunia [ Time Frame: 3, 6, and 9 months ] [ Designated as safety issue: No ]
  • Evaluate toxicity of two dose levels of megestrol acetate relative to placebo [ Time Frame: 3, 6, and 9 months ] [ Designated as safety issue: Yes ]
  • Feasibility of accrual patients to placebo-controlled study [ Time Frame: At registration ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
S9626: Megestrol in Treating Hot Flashes Following Treatment for Breast Cancer
A Phase III Trial of Placebo Versus Megestrol Acetate 20 MG/Day Versus Megestrol Acetate 40 MG/Day as Treatment for Symptoms of Ovarian Failure in Women Treated for Breast Cancer: SWOG Study S9626

RATIONALE: Megestrol may be effective in treating hot flashes following treatment for breast cancer. It is not yet known which regimen of megestrol is most effective for hot flashes.

PURPOSE: Randomized phase III trial to compare the effectiveness of different doses of megestrol in treating hot flashes in patients who have undergone therapy for breast cancer.

OBJECTIVES: I. Compare the effectiveness and duration of the benefit of placebo versus low dose megestrol versus high dose megestrol in the reduction of severe and/or frequent hot flashes in patients with previously treated invasive breast cancer. II. Document the effects of various dose levels of megestrol on atrophic vaginitis and dyspareunia in these patients. III. Evaluate the toxicity of this treatment in these patients.

OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study. Patients are stratified according to tamoxifen use (yes vs no), number of hot flashes per week (5-34 vs 35-63 vs more than 63), and duration of hot flashes (6 months or less vs longer than 6 months). Patients are randomized to one of three treatment arms. Arm I: Patients receive oral placebo daily. Arm II: Patients receive lower dose oral megestrol daily. Arm III: Patients receive higher dose oral megestrol daily. Patients who do not respond after 3 months of treatment receive an additional dose of oral megestrol daily. Treatment continues for a total of 6 months in the absence of disease progression or unacceptable toxicity. Patients are followed at 3 months.

PROJECTED ACCRUAL: A total of 279 eligible patients (93 per arm) are expected to be accrued.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Supportive Care
  • Breast Cancer
  • Hot Flashes
  • Drug: Megestrol Acetate 20mg/day
    Double blinded Megestrol Acetate 20 mg/day
    Other Name: NSC-71423
  • Drug: Megestrol Acetate 40 mg/day
    Double blinded Megestrol Acetate 40 mg/day
    Other Name: NSC-71423
  • Drug: Megestrol Acetate Placebo 20 mg/day
    Megestrol Acetate Placebo 20 mg/day
    Other Name: NSC-71423
  • Drug: Megestrol Acetate Placebo 40 mg/day
    Megestrol Acetate Placebo 40 mg/day
    Other Name: NSC-71423
  • Active Comparator: Megestrol Acetate/Placebo 20 mg/day
    Double blinded Megestrol Acetate 20 mg/day or Megestrol Acetate Placebo 20 mg/day taken for 3 months
    Interventions:
    • Drug: Megestrol Acetate 20mg/day
    • Drug: Megestrol Acetate Placebo 20 mg/day
  • Active Comparator: Megestrol Acetate/Placebo 40 mg/day
    Double blinded Megestrol Acetate 40 mg/day or Megestrol Acetate Placebo 40 mg/day taken for 3 months
    Interventions:
    • Drug: Megestrol Acetate 40 mg/day
    • Drug: Megestrol Acetate Placebo 40 mg/day
Goodwin JW, Green SJ, Moinpour CM, Bearden JD 3rd, Giguere JK, Jiang CS, Lippman SM, Martino S, Albain KS. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. J Clin Oncol. 2008 Apr 1;26(10):1650-6. doi: 10.1200/JCO.2006.10.6179.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
288
March 2002
September 2001   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS: Diagnosis of infiltrating breast cancer (T1-3, N0-1, M0) treated with appropriate local and regional therapy Chemotherapy and/or surgery completed At least 10 hot flashes per week OR At least 5 severe or very severe hot flashes per week No prior participation in NCI sponsored breast cancer adjuvant protocol No recurrent or persistent vaginal bleeding If postmenopausal and had any vaginal bleeding within past year, then must have normal endometrial biopsy Hormone receptor status: Not specified

PATIENT CHARACTERISTICS: Age: Not specified Menopausal status: Pre or postmenopausal Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Cardiovascular: No history of deep vein thrombosis Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No other prior malignancy in past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other adequately treated stage I or II cancer

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics No concurrent chemotherapy Endocrine therapy: Prior hormonal therapy allowed At least 6 months since prior megestrol At least 1 week since prior nonestrogen containing steroid hormones (except tamoxifen) Concurrent tamoxifen allowed only if begun at least 4 months prior to study No other concurrent nonestrogen containing steroid hormones No concurrent estrogen or hormone replacement therapy Radiotherapy: Concurrent radiotherapy allowed Surgery: See Disease Characteristics Prior hysterectomy allowed No concurrent surgery Other: Concurrent nonhormonal prescription or nonprescription medications for hot flashes allowed (e.g., clonidine, ergotamine tartrate, vitamin E, or soy)

Female
up to 120 Years   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00005975
CDR0000067962, S9626, NCI-P00-0159, U10CA037429
Yes
Not Provided
Not Provided
Southwest Oncology Group
Southwest Oncology Group
National Cancer Institute (NCI)
Study Chair: John W. Goodwin, MD Cancer Research for the Ozarks
Southwest Oncology Group
November 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP